Sponsored and Hosted by Bristol Meyers Squibb, Seminar Director: Dr Richard Westhouse,
The Topic for this Day Seminar will be: Translational Research Starts With Pathology
Sub-Division Program Director; Dr. Zadok Ruben
COST: ALL ATTENDEES MUST REGISTER FOR THIS COURSE.
Active individual, University, and Corporate Members of the Foundation may register at no charge. The following organizations have current memberships: Abbott, ABBVIE, Bristol Meyers Squibb, Biogen, Charles River, EPL, Genetech, Janssen, MedImmune, Merck, and Novartis.
Members of the facility (Bristol Myers Squibb) may register at no charge.
Non-Members will be registered for $110, which includes a year's active individual membership in the Foundation.
Translational Research is increasingly recognized as significantly improving pharmaceutical and basic research in disease. Collaborations between clinicians and investigators, at all levels, increases the chances of successful outcomes through such means as the use of predictive biomarkers, efficacy models, etc. to guide clinical study design, but also more efficient discovery of optimized exploratory drugs through clinical study design, but more efficient discovery of optimized exploratory drugs through the use of patient samples. This day seminar will present the evolving role of pathology with reference to the contributions of veterinary pathologists. While some collaborations, such as on efficacy models, have remained fairly similar over the years, veterinary pathologists now utilize new applications and methodologies for image analysis, tissue banking, molecular phenotyping, etc., for the purpose of providing a more integrated-comparative approach to translational research.
Bruce Car, Vice President, Translational Sciences: Translational Research: Strategies for Building an Effective Organization
Myrtle Davis, Chief, Toxicology and Pharmacology Branch National Cancer Institute: Perspectives on the use of image analysis in Investigative Toxicology
Shuyan Du, Director Imaging: Clinical Translational Technologies & Operations: Translational Research Begins with P In Vivo Imaging.
Dr. Stephen C. Jameson, Department of Laboratory Medicine and Pathology, University of Minnesota Medical School: Of Mice, Dirty Mice, and Men: Using Mice to Understand Human Immunology
Dr. Robin Edwards, Group Director, Pathology, Bristol-Myers Squibb: New Approaches to Dissecting the Tumor Microenvironment
Dr. Dan Seekins, Group Medical Director, Medical Safety Assessment Lead, Bristol-Myers Squibb: IQ-DILI: Best Practices for the Detection, Monitoring, Management and Prevention of Drug Induced Liver Injury in Clinical Trials and in Post-Marketing Pharmacoviligance Activities
The following corporations are members of the Foundation and their members are free.
Abbott, ABBVIE, Bristol Meyers Squibb, Biogen, Charles River, EPL, Genetech, Janssen, MedImmune, Merck, and Novartis